Skip to main
GUTS

GUTS Stock Forecast & Price Target

GUTS Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 0%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Fractyl Health is well-positioned for success with their novel approach to treating obesity and type 2 diabetes, demonstrated by positive clinical trial results for their lead product candidate Revita and the recent authorization for a clinical trial for their gene therapy candidate. They are also benefiting from the new RAPID pathway for medical device coverage, which could shorten reimbursement timelines and increase market access. With plans for regulatory milestones and a strong financial outlook, Fractyl is a promising investment opportunity for those with a positive outlook on their innovative therapies for metabolic disease.

Bears say

Fractyl Health is facing potential risks with their lead product candidate Revita, as data shows a high rate of weight regain in patients after discontinuing treatment with similar GLP-1 drugs. While the company has received FDA breakthrough designation and is targeting Medicare beneficiaries for faster coverage and adoption, the requirement for patients to maintain a 5% weight loss may pose a challenge given the observed weight regain rate. Additionally, the company's YE26 price target of $8 per share is based on an aggressive sum-of-the-parts peak revenue analysis with high multiples.

GUTS has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 0% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fractyl Health Inc (GUTS) Forecast

Analysts have given GUTS a Strong Buy based on their latest research and market trends.

According to 5 analysts, GUTS has a Strong Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fractyl Health Inc (GUTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.